@entity4770 ( @entity4770 ) is a lipid mediator with vasodilatory and antithrombotic effects used in the treatment of vasoconstrictive/ischemic diseases including @entity120 . However, emerging research supports a role for PGs, including PGI(2), in the regulation of both innate and acquired immunity. As PGI(2) is unstable, we sought to define the effects of various @entity4770 analogs on resident alveolar macrophage (AM) and peritoneal macrophage (PM) innate immune functions. The effects of iloprost, @entity32101 , and @entity13992 on the regulation of phagocytosis, bacterial killing, and inflammatory mediator production were determined in both macrophage populations from @entity35 . Iloprost failed to suppress AM functions to the same degree that it did in PMs, a characteristic shared by @entity32101 . This difference reflected greater expression of the G(alphas) protein-coupled I prostanoid receptor and greater @entity268 generation in PMs than AMs. @entity13992 inhibited phagocytosis, bacterial killing, and cytokine generation in AMs to a much greater degree than the other PGI(2) analogs and more closely resembled the effects of @entity1421 . Studies with the E prostanoid (EP) 2 receptor antagonist @entity43507 and @entity7701 -null macrophages indicated that this was due in part to the previously unknown ability of @entity13992 to stimulate the @entity7701 receptor. The present investigation for the first time identifies differences in immunoregulatory properties of clinically administered PGI(2) analogs. These studies are the first to explore the capacity of PGI(2) to regulate bacterial killing and phagocytosis in macrophages, and our findings may hold important consequences regarding the risk of @entity281 for @entity1 receiving such agents.

Synthetic XXXX analogs differentially regulate macrophage function via distinct analog-receptor binding specificities.

@entity268 :: ('CHEBI:17489', 'Chemical') :: ['cAMP'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity43507 :: ('MESH:C053876', 'Chemical') :: ['AH-6809'] @entity1421 :: ('MESH:D015232', 'Chemical') :: ['PGE(2)'] @entity120 :: ('MESH:D006976', 'Disease') :: ['pulmonary artery hypertension'] @entity4770 :: ('MESH:D011464', 'Chemical') :: ['PGI(2)', 'prostacyclin'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity32101 :: ('MESH:C026678|MESH:C530152', 'Chemical') :: ['carbaprostacyclin'] @entity13992 :: ('MESH:C427248', 'Chemical') :: ['treprostinil', 'Treprostinil'] @entity7701 :: ('5732', 'Gene') :: ['EP2'] @entity35 :: ('10116', 'Species') :: ['rats']
@entity4770 :: (MESH:D011464,Chemical) :: ['prostacyclin']
